Composition for improving scalp condition containing gluconolactone and crimbazole as active ingredients

Abstract

The composition for improving scalp condition of the present invention has a remarkably excellent anti-inflammatory effect due to the synergistic effect of the combination of gluconolactone and climbazole, and therefore has a remarkably excellent effect of improving dandruff, scalp itching, scalp keratinization, or seborrheic scalp inflammation. In addition, the composition for improving scalp condition of the present invention has a remarkably excellent effect of strengthening the scalp barrier by reducing the amount of transepidermal water loss. In addition, the composition for improving scalp condition of the present invention has a far superior effect of improving keratin shedding, scalp odor, or scalp irritation.

Description

Technical Field

[0001] The present invention relates to a composition for improving scalp condition.

[0002] This application claims priority based on Korean Patent Application No. 10-2022-0035446 filed on March 22, 2022 and Korean Patent Application No. 10-2022-0082719 filed on July 5, 2022, and all the contents disclosed in the specifications and drawings of the applications are incorporated into this application.

Background Art

[0003] In modern society, many people use various products to clean their scalps and hair to make them clean. However, since the main components of such products include surfactants, foam boosters, emulsifiers, thickeners, and preservatives, etc., there is a risk of inducing irritation and itching on the scalp.

[0004] Also, many people use hair dyes or perm agents, etc. to change their hairstyles for beauty purposes. In the case of some sensitive scalps, damage may occur to the scalp due to physical and chemical stimuli caused by hair dyes or perm agents, etc.

[0005] In daily life, changes in temperature and humidity, exposure to sunlight, or pollutants such as fine dust may also stimulate the scalp, and in addition, scalp conditions may deteriorate due to stress, nutritional deficiencies, etc.

[0006] The scalp is composed of the epidermis, dermis, and subcutaneous tissue.

[0007] Normally, the stratum corneum of the scalp undergoes a process called turnover, where it is replaced with new keratinocytes in a cycle of approximately one month. In a healthy scalp, during stratum corneum turnover, small keratinocytes are shed and replaced with new keratinocytes. However, if the turnover deviates from a steady state and there is an excess of keratinocytes in certain areas, they may shed in visible clumps, which is called dead skin cells. While dead skin cells are a scalp issue, they do not pose a significant health problem and occur to varying degrees in most people's scalps.

[0008] Known causes of scalp buildup include increased sebum secretion on the scalp, proliferation and increased activity of microorganisms, abnormal keratinization due to abnormal scalp metabolism, or scalp irritation caused by fatty acids produced by lipase.

[0009] When excessive hair growth occurs, itching can lead to scratching or rubbing of the scalp, causing physical irritation that can result in wounds or inflammation. The itching that occurs at this time can be mediated by histamine and arachidonic acid metabolites, which trigger a complex inflammatory response that stimulates nerve cells and induces itching.

[0010] Furthermore, related to the symptoms of scalp odor, sebum secretion, sweat, and keratinization by microorganisms on the scalp induce scalp odor. These waste products can oxidize and produce an unpleasant odor on the scalp. Scalp odor is related to the distribution of microorganisms, as the scalp is more susceptible to the formation of a microbial habitat (hair, humidity, etc.) than other parts of the skin.

[0011] The most commonly used active ingredient in commercially available anti-scalp shampoos is zingucrose pyrithione. Zingucrose pyrithione has antimicrobial properties, a high specific gravity, is insoluble in water, and is difficult to maintain in dispersion within a dosage form. Furthermore, because zingucrose pyrithione is irritating, research and development are gradually underway in Japan to replace it with other ingredients.

[0012] Attempts have been made to suppress the production of smegma or alleviate scalp itchiness by applying or ingesting natural ingredients such as existing plant extracts to the scalp. However, these methods have the drawback of not being highly effective in improving smegma, excessive shedding of dead skin cells, keratinization, or itchiness. Therefore, there is a need to develop compositions for improving scalp conditions that are effective in improving smegma, excessive shedding of dead skin cells, keratinization, or itchiness. [Overview of the project] [Problems that the invention aims to solve]

[0013] The present invention aims to provide a composition for improving scalp condition that is safe for the human body, has excellent dosage form stability, and can maintain a healthy scalp. [Means for solving the problem]

[0014] The inventors of this invention diligently researched the development of a composition capable of improving scalp condition and found that when gluconolactone and climbazole are used in combination as active ingredients in a composition for improving scalp condition, the scalp condition is significantly improved. Specifically, the composition for improving scalp condition of this invention exhibits excellent anti-inflammatory effects due to the synergistic effect of the combination of gluconolactone and climbazole, resulting in outstanding effects in improving scalp dirt, scalp itchiness, keratin shedding, scalp keratin thickening, and seborrheic dermatitis. Furthermore, the composition for improving scalp condition of this invention exhibits excellent effects in strengthening the scalp barrier by reducing transepidermal water loss. In addition, the inventors of this invention confirmed through sensory evaluation that the above-mentioned composition for improving scalp condition is outstanding in improving scalp itchiness, scalp dirt, keratin shedding, scalp keratin thickening, scalp odor, and scalp irritation, leading to the completion of this invention.

[0015] The present invention provides a composition for improving scalp condition containing gluconolactone and crimbazole as active ingredients. This composition for improving scalp condition can improve scalp dirt, scalp itchiness, scalp keratinization, or seborrheic dermatitis by significantly suppressing the secretion of inflammatory factors, and is also far superior in its effects on improving keratin shedding or scalp odor. The inflammatory factors may be, for example, interleukin-8, but are not limited thereto. Furthermore, this composition can strengthen the scalp barrier by reducing transepidermal water loss in the scalp.

[0016] In one embodiment of the present invention, the gluconolactone may be present in an amount of 0.001 to 20% by weight, preferably 0.01 to 10% by weight, relative to the total weight of the composition. Furthermore, the crimbazole may be present in an amount of 0.001 to 20% by weight, preferably 0.001 to 5% by weight, and more preferably 0.01 to 0.5% by weight, relative to the total weight of the composition. If the amount of gluconolactone and crimbazole is less than 0.001% by weight each, the effect of improving scalp condition is slight, and if it exceeds 20% by weight, the dosage form stability is reduced, which is undesirable.

[0017] In one embodiment of the present invention, the weight ratio of gluconolactone to crimbazole may be 1:0.01 to 10, preferably 1:0.03 to 5, and more preferably 1:0.05 to 3 (gluconolactone:crimbazole). When the weight ratio of the two components is within the above range, the scalp condition improving effect of the composition for improving scalp condition is remarkably excellent.

[0018] In one embodiment of the present invention, the composition for improving scalp condition can be formulated into any form that is normally applicable to the skin, but preferably into a topical formulation. For example, the composition for improving scalp condition can be manufactured into a formulation applicable to the skin, such as a liquid, cream, paste, spray, or solid.

[0019] In one embodiment of the present invention, the composition for improving scalp condition may be a cosmetic composition or a functional cosmetic composition, and such a cosmetic composition or functional cosmetic composition can be manufactured by conventional methods in the field of cosmetics, by adding conventional ingredients. Furthermore, the composition for improving scalp condition may be a pharmaceutical or quasi-drug composition.

[0020] In one embodiment of the present invention, when the dosage form of the composition is liquid, a solvent, solubilizer, or emulsifier is used as the carrier component. For example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan may be used.

[0021] In one embodiment of the present invention, if the dosage form of the composition is a paste, cream, or gel, then animal oils, vegetable oils, waxes, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as the carrier component.

[0022] In one embodiment of the present invention, when the dosage form of the composition is a powder or a spray, the carrier component may be lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder. In particular, when the dosage form of the composition is a spray, it may further contain propellants such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether.

[0023] In one embodiment of the present invention, the components included in the composition may include, in addition to gluconolactone and crimbazole, components commonly used in topical preparations applicable to the skin. For example, it may further include one or more additives selected from the group consisting of water, surfactants, humectants, lower alcohols, chelating agents, bactericides, antioxidants, preservatives, dyes, and fragrances.

[0024] In addition, the present invention provides a scalp improvement method including a step of administering or applying the composition to a subject or the skin of a subject who needs scalp improvement, and / or a step of improving the scalp of the subject or the skin of the subject. Desirably, the scalp improvement may be improvement of dandruff, improvement of scalp itching, improvement of scalp keratin hyperplasia, improvement of seborrheic dermatitis, improvement of keratin exfoliation, or improvement of scalp odor.

[0025] In one embodiment of the present invention, the composition for improving scalp condition can be manufactured into a shampoo dosage form (Production Example 1).

[0026] In the present invention, the composition for improving scalp condition can be used by a transdermal administration method such as direct application or sprinkling on the skin. When the composition is in the form of a shampoo, it is desirable to wash after foaming and applying to the scalp and hair in the usual shampoo usage method.

[0027] In the present invention, the term "administration" means introducing the composition of the present invention by any suitable method. The administration route of the composition of the present invention can be administered by any general route as long as it can reach the target tissue. Desirably, the composition can be administered transdermally and desirably can be locally applied. The number of applications of the composition of the present invention can be determined according to the prescription, necessity, or desire.

[0028] In addition, the present invention provides a product for hair or scalp, which contains the composition for improving scalp condition. The product for hair or scalp may be added with ordinary additives, and can be manufactured into products such as scalp cleansing agents, scalp scaling agents, scalp massage agents, scalp care agents, shampoos, tonics, hair conditioners, hair lotions, gels, packs, creams, essences, powders, sprays, oils, soaps, ointments, hair styling agents, hair growth agents, hair dyes, and perm agents for improving scalp condition, but is not limited thereto. Further, the composition for improving scalp condition may also be used in the form of an aerosol type of the dosage form. In addition, the composition of the present invention can also be manufactured as a composition or product for use on eyebrows or eyelashes in addition to the scalp.

[0029] In one embodiment of the present invention, the amount of use of the composition for improving scalp condition can be appropriately adjusted according to individual differences such as age and degree of lesion, or according to the dosage form. Desirably, the amount of use of the composition for improving scalp condition can usually be used in an appropriate amount, once to several times a day, continuously on the scalp for one week to several months. In Experimental Example 1 of the present invention, a synergistic effect of gluconolactone and climbazole on inflammation suppression was confirmed. In Experimental Example 2, when the composition for improving scalp condition of the present invention was used 3 ml each time, once a day for 14 days, it was confirmed that the effect of improving scalp condition was significantly excellent compared with the comparative example.

[0030] All components described in the present invention desirably do not exceed the maximum amount of use specified by relevant laws and regulations, such as those in South Korea, China, the United States, Europe, Japan, etc. (for example, regulations regarding cosmetic safety standards (South Korea), cosmetic safety technical specifications (China), food code (South Korea), food additive code (South Korea), health functional food code (South Korea)). That is, desirably, the composition for improving scalp condition, cosmetic composition, functional cosmetic composition, pharmaceutical composition or quasi-drug composition according to the present invention contains the components according to the present invention within the limits of the content allowed by relevant laws and regulations of each country.

Effects of the Invention

[0031] The scalp condition improving composition of the present invention exhibits remarkably excellent anti-inflammatory effects due to the synergistic effect of the combination of gluconolactone and crimbazole, resulting in remarkably excellent effects in improving scalp dirt, scalp itchiness, keratin thickening, and seborrheic dermatitis. Furthermore, the scalp condition improving composition of the present invention exhibits remarkably excellent effects in strengthening the scalp barrier by reducing transepidermal water loss in the scalp. In addition, the scalp condition improving composition of the present invention exhibits remarkably excellent effects in improving keratin shedding, scalp odor, and scalp irritation. [Brief explanation of the drawing]

[0032] [Figure 1] This graph shows the improvement in TEWL (transcutaneous water loss) when using a shampoo containing gluconolactone and crimbazole. [Figure 2] This image illustrates the improvement in keratin thickening when using a shampoo containing gluconolactone and crimbazole. [Figure 3] This graph shows the improvement in scalp itchiness, exfoliation, scalp odor, and irritation experienced by users when using a shampoo containing gluconolactone and crimbazole. [Modes for carrying out the invention]

[0033] The present invention will be described in detail below with reference to examples and other details to aid in understanding the present invention. However, the examples of the present invention can be modified into a variety of other forms, and the scope of the present invention should not be construed as being limited to the examples described below. The examples of the present invention are provided to give a more complete explanation of the present invention to a person with average skill in the art to which the present invention belongs.

[0034] Experimental Example 1: Confirmation of anti-inflammatory effect (1) Evaluation of the rate of suppression of inflammatory response To confirm the anti-inflammatory activity of gluconolactone and clinbazole, their ability to suppress the production of nitric oxide (NO), one of the substances that induce inflammation, was analyzed. The RAW 264.7 cells used in the experiment are a murine macrophage cell line, which was used as the primary model for anti-inflammatory cell activity experiments and was purchased from ATCC (American Type Tissue Collection). The RAW 264.7 cells were cultured in RPMI1640 (Gibco) medium containing 10% FBS (fetal bovine serum, Gibco) and 1% penicillin / streptomycin (Gibco).

[0035] To confirm the anti-inflammatory activity of gluconolactone and crimbazole, the aforementioned RAW 264.7 cells were placed in a 96-well plate at a rate of 2.0 × 10⁶ cells per well. 4 Cells were dispensed, attached to the cells, and cultured for 24 hours. Subsequently, they were simultaneously treated with 1 μg / mL of lipopolysaccharide (LPS), gluconolactone, and crimbazole for 24 hours, and the ability to inhibit NO production was analyzed by the Griess reaction.

[0036] The Gries reaction described above is a method for quantitatively analyzing the amount of NO produced from cells treated with a sample and released into the culture medium. The Gries reaction solution is prepared by mixing a 1% sulfanilamide solution dissolved in a 5% phosphoric acid solution with a 0.1% naphthylenediamine dihydrochloride solution in a 1:1 ratio.

[0037] After 24 hours of treatment, 50 μL of cell culture medium was taken from each well and dispensed into a 96-well plate. Then, 50 μL of the prepared Gries reaction solution was dispensed per well in the same volume as the cell culture medium, and the color change due to NO production and inhibition was measured by absorbance at 540 nm using a multi-plate reader. The experimental results are shown as the average of 3 replicates for each gluconolactone and clinbazole treatment combination.

[0038] Next, to confirm whether gluconolactone and clinbazole induced cytotoxicity, the CCK-8 assay (Cell Counting Kit-8, Dojindo) was performed using 50 μL of cell culture medium. The CCK-8 assay is one method for measuring cell viability. After adding 1 / 10 the assay reaction solution to the cell culture medium and reacting at 37°C for one hour, the absorbance at 450 nm was measured using a multiplate reader. No cytotoxicity was observed between the measured concentrations.

[0039] The NO inhibitory activity induced by LPS was expressed as a percentage compared to a control group (A) that was not treated with either LPS or the sample, and a control group (B) that was treated with LPS only but not the sample. The formula for calculating the percentage of anti-inflammatory activity in each sample (C) is as follows. Inflammation inhibitory activity (%)={(BC) / (BA)}×100

[0040] A is the absorbance of the control group in which neither LPS nor the sample was treated at 540 nm, B is the absorbance of the control group in which only LPS was treated at 540 nm, and C is the absorbance of the experimental group in which both LPS and the sample were treated at 540 nm.

[0041] The calculated values ​​for the anti-inflammatory activity of gluconolactone and crimbazole according to the present invention are shown in Table 1 below. [Table 1]

[0042] The experimental results described in Table 1 confirm the suppression of inflammatory responses by gluconolactone or crimbazole, and in particular, it can be seen that the rate of inflammatory response suppression increases significantly when gluconolactone and crimbazole are applied together.

[0043] (2) Investigation of the anti-inflammatory synergistic effect of gluconolactone and crimbazole When gluconolactone and crimbazole are used together, the expected value (rate of inflammation suppression) was calculated using Colby's formula. The calculation process and results are shown below. "Synergistic effect" is defined as follows: "Calculation of the synergistic and antagonistic responses of herbicide combinations," Weeds, (1967), pp. 15, 20-22. Colby's formula: Expected value = A + B - (A × B / 100) A: Efficacy observed from active ingredient A at the same concentration used in the mixture. B: Efficacy observed from active ingredient B at the same concentration used in the mixture.

[0044] To calculate the expected rate of inflammation suppression when gluconolactone and climbazole are used together, the inflammation suppression rate of the experimental group treated with only LPS and gluconolactone was substituted into A of Colby's equation, and the inflammation suppression rate of the experimental group treated with only LPS and climbazole was substituted into B. The expected value using Colby's equation was then calculated, and the resulting value is shown in Table 2 below.

[0045] Furthermore, the degree of synergy effect was calculated and is shown in Table 2 below. The values ​​in Table 2 were rounded to two decimal places and expressed to one decimal place. [Table 2]

[0046] From the results shown in Table 2 above, it can be confirmed that the actual rate of suppression of inflammatory response when using gluconolactone and crimbazole together was approximately 14.4% higher than the expected value predicted when using gluconolactone and crimbazole together, when both substances were used at a concentration of 25 μM each. In other words, the combination of gluconolactone and crimbazole shows a remarkable synergistic effect in suppressing inflammatory responses.

[0047] Experiment Example 2: Evaluation of Scalp Condition Improvement To confirm the efficacy of the scalp condition improving composition produced by the present invention, a scalp condition improving composition (shampoo) containing gluconolactone and crimbazole was produced in Example 1, and a composition without gluconolactone and crimbazole was produced in Comparative Example 1 (see Table 8).

[0048] The experimental group consisted of 12 adults aged 26-45 who experienced scalp itchiness. They were divided into two groups of six. The product evaluated was a wash-off type shampoo. After using 3 ml of the product once a day for two weeks, the degree of improvement in scalp condition was evaluated using the following items.

[0049] (1) Evaluation of transcutaneous water loss (TEWL) of the scalp Transepidermal water loss indicates the degree to which water evaporates from within the skin and tends to increase when the skin's barrier function is damaged.

[0050] To measure the transcutaneous water loss of the scalp of experimental subjects more than 8 hours after washing their hair, the scalp was allowed to be exposed to constant temperature and humidity conditions (23°C, 40% relative humidity) for 20 minutes. After 20 minutes of exposure, the transcutaneous water loss was measured at four points: the top of the head, the crown, the forehead, the back of the head, and the midline of the head, using a transcutaneous water loss analyzer (Tewameternano probe, MPA6, C+K Electronic Co., Germany).

[0051] Subsequently, the compositions for improving scalp condition (Comparative Example 1 and Example 1) were used for two weeks each, and the amount of transcutaneous water loss in the same area was measured one and two weeks after the use of the compositions. One person who used Comparative Example 1 discontinued the study midway through.

[0052] The measurement results, the average for each comparative example group of 5 people and the average for example group of 6 people, are shown in Table 3 and Figure 1. [Table 3]

[0053] As can be seen from Table 3 and Figure 1, when Example 1, a composition for improving scalp condition containing gluconolactone and crimbazole, was used, the amount of transepidermal water loss was significantly reduced compared to when Comparative Example 1, a control group that did not contain gluconolactone and crimbazole, was used.

[0054] (2) Evaluation of improvement in thickened keratin of the scalp To evaluate the efficacy of the composition for improving scalp condition of the present invention in improving keratin thickening, keratin was collected from the scalps of the aforementioned experimental subjects and its thickness was analyzed.

[0055] Thickened keratinized cells of the scalp were analyzed using Visioscan VC98 (C+K Electronic Co., Germany). For keratin collection and measurement, a special tape called Black D-Squame tape was prepared in a 0.5cm x 2.5cm size and attached to the scalp surface at four intersections of the scalp and the midline of the scalp: the top of the head, the crown, the forehead, and the back of the head. After 10 seconds, the tape was peeled off and attached to the Visioscan (CCD-camera) for imaging to measure the amount of keratin collected. Since it is difficult to eliminate interference from hair in the desquamation index provided after analysis by software and the total amount of collected keratin, the ratio of the thickest keratinized cell (G4) to the total area of ​​the collected and analyzed keratinized cells (G0 + G1 + G2 + G3 + G4) was defined as the "percentage of thickened keratinized cells" and analyzed. Percentage of thickened keratin = G4 / (G0+G1+G2+G3+G4)

[0056] The parameters G0, G1, G2, G3, and G4 mentioned above are defined in "Relationship between lip skin biophysical and biochemical characteristics with corneocyte unevenness ratio as a new parameter to assess the severity of lip scaling," International Journal of Cosmetic Science (2021), Vol. 43, Issue 3, pp. 275-282.

[0057] The percentage of thickened keratin is expressed as an improvement rate relative to the measurement taken before product use (week 0), and the formula for calculating the improvement rate is as follows. Improvement rate of keratin thickening = (ab) / a × 100 a: Percentage of thickened keratin before product use b: Percentage of thickened keratin after product use

[0058] The measurement results, including the average of 5 people in each Comparative Example 1 group and the average of 6 people in Example 1 group, are shown in Table 4. Representative images of the Example 1 group before and after using the product are shown in Figure 2. [Table 4]

[0059] As can be seen from Table 4 and Figure 2, when Example 1, a composition for improving scalp condition containing gluconolactone and crimbazole, was used, keratin thickening was improved compared to when Comparative Example 1, a control group that did not contain gluconolactone and crimbazole, was used.

[0060] (3) Analysis of interleukin-8 collected from the stratum corneum To confirm the efficacy of the composition for improving scalp condition of the present invention in improving the secretion of inflammatory factors, the content of interleukin-8 in keratinocytes was analyzed using keratinocytes collected from the scalps of the aforementioned experimental subjects.

[0061] Interleukin-8 (IL-8) is a representative inflammatory factor known to increase in keratin samples from lesions such as scalp smegma and seborrheic dermatitis, as reported in literature such as "Dandruff / seborrhoeic dermatitis is characterized by an inflammatory genomic signature and possible immune dysfunction: transcriptal analysis of the condition and treatment effects of zinc pyrithione," British Journal of Dermatology (2012), Vol 166, Issue S2, pp. 33-40.

[0062] For keratin collection, a special tape called Black D-Squame tape was prepared in a 0.5cm x 2.5cm size and applied to the scalp surface of the subject's head at four intersections: the top of the head, the vertex, the forehead, the back of the head, and the midline of the head, for 10 seconds. After removing the tape, the collected keratin was eluted using 1×PBS containing 0.05% Tween 20 + 0.5mM EDTA. The keratin was sonicated with a buffer solution for 60 minutes, and the eluted keratin solution was quantitatively analyzed using the Human IL-8 ELISA kit (R&D system).

[0063] Furthermore, the total amount of protein in the eluted keratin solution was confirmed using the BCA Protein Assay (ThermoFisher Scientific), and the amount of IL-8 in the keratin was analyzed after normalization to the total protein amount.

[0064] The IL-8 analysis results are shown in Table 5, with the average for each Comparative Example 1 group of 5 people and the average for Example 1 group of 6 people. [Table 5]

[0065] As can be seen from Table 5 above, when Example 1, a composition for improving scalp condition containing gluconolactone and crimbazole, was used, IL-8 secretion was improved compared to when Comparative Example 1, a control group that did not contain gluconolactone and crimbazole, was used.

[0066] (4) Sensory evaluation To confirm the efficacy of the scalp condition improving composition manufactured according to the present invention, a sensory evaluation was conducted by administering a questionnaire to the experimenters who participated in the evaluation, with the following items. The products evaluated were the wash-off type shampoos of Comparative Example 1 and Example 1. After using each product once a day for one week, the subjective degree of improvement in scalp condition was confirmed by administering a questionnaire, with the evaluation scale ranging from 0 to 5 points. The self-diagnosis criteria for each item are shown in Table 6 below. [Table 6]

[0067] The results of the sensory evaluation are the average of the 5 people in each Comparative Example 1 group and the average of the 6 people in each Example 1 group, and are shown in Table 7 and Figure 3 below. [Table 7]

[0068] As can be seen from Table 7 and Figure 3 above, when Example 1, a composition for improving scalp condition containing gluconolactone and crimbazole, was used, scalp itching, exfoliation, and scalp odor were significantly improved, and scalp irritation was also reduced, compared to when Comparative Example 1, a control group that did not contain gluconolactone and crimbazole, was used.

[0069] From the experimental results described above, it can be seen that the scalp condition improving composition of the present invention, through the combination of gluconolactone and crimbazole, exhibits remarkably excellent effects in improving transepidermal water loss, keratin thickening, IL-8 secretion, scalp itchiness, keratin shedding, and scalp odor.

[0070] Manufacturing Example 1: Composition 1 for improving scalp condition (shampoo) [Table 8]

[0071] Manufacturing Example 2: Composition 2 for improving scalp condition (hair tonic) A hair tonic composition was prepared using gluconolactone and crimbazole according to the formulations shown in Table 9 below, using a standard method. [Table 9]

[0072] Manufacturing Example 3: Composition 3 for improving scalp condition (hair lotion) A hair lotion composition was prepared using gluconolactone and crimbazole in a conventional manner according to the formulations shown in Table 10 below. [Table 10]

Claims

1. It contains gluconolactone and crimbazole as active ingredients. A composition for improving scalp condition, wherein the weight ratio of gluconolactone to crimbazole is 1:0.05 to 3 (gluconolactone:crimbazole).

2. The composition for improving scalp condition according to claim 1, wherein the amount of gluconolactone is 0.001 to 20% by weight of the total weight of the composition.

3. The composition for improving scalp condition according to claim 1, wherein the amount of crimbazole is 0.001 to 20% by weight of the total weight of the composition.

4. The composition for improving scalp condition according to claim 1, wherein the composition suppresses the secretion of inflammatory factors.

5. The composition for improving scalp condition according to claim 1, wherein the composition improves moisture loss from the scalp and strengthens the scalp barrier.

6. The composition for improving scalp condition according to claim 1, wherein the composition is for improving scalp dirt, improving thickening of the keratin layer of the scalp, or improving symptoms of keratin shedding.

7. The composition for improving scalp condition according to claim 1, wherein the composition is a cosmetic composition.

8. A product for hair or scalp comprising the composition for improving scalp condition described in claim 1.

9. The hair or scalp product according to claim 8, wherein the product is selected from the group consisting of scalp cleansing agents, scalp scaling agents, scalp massage agents, scalp care agents, cleansing agents, shampoos, tonics, hair conditioners, hair lotions, gels, packs, creams, essences, powders, sprays, oils, soaps, ointments, hair styling agents, hair growth agents, hair dyes, and perming agents.

Images